CN110337444A - 穿越血脑屏障的纳米药物载体 - Google Patents
穿越血脑屏障的纳米药物载体 Download PDFInfo
- Publication number
- CN110337444A CN110337444A CN201880010782.3A CN201880010782A CN110337444A CN 110337444 A CN110337444 A CN 110337444A CN 201880010782 A CN201880010782 A CN 201880010782A CN 110337444 A CN110337444 A CN 110337444A
- Authority
- CN
- China
- Prior art keywords
- ferritin
- people
- albumen
- sequence
- caged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008499 blood brain barrier function Effects 0.000 title claims abstract description 81
- 210000001218 blood-brain barrier Anatomy 0.000 title claims abstract description 80
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 239000012634 fragment Substances 0.000 claims abstract description 47
- 102000008857 Ferritin Human genes 0.000 claims abstract description 43
- 108050000784 Ferritin Proteins 0.000 claims abstract description 43
- 238000008416 Ferritin Methods 0.000 claims abstract description 43
- 102000005962 receptors Human genes 0.000 claims abstract description 41
- 108020003175 receptors Proteins 0.000 claims abstract description 41
- 239000003937 drug carrier Substances 0.000 claims abstract description 19
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract description 15
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 9
- 206010051290 Central nervous system lesion Diseases 0.000 claims abstract description 8
- 108010002084 Apoferritins Proteins 0.000 claims description 202
- 102000000546 Apoferritins Human genes 0.000 claims description 202
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 80
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 claims description 74
- 229940079593 drug Drugs 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 101800001509 Large capsid protein Proteins 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 238000001338 self-assembly Methods 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 14
- 229940009456 adriamycin Drugs 0.000 claims description 12
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 10
- 208000014644 Brain disease Diseases 0.000 claims description 10
- 150000001413 amino acids Chemical group 0.000 claims description 10
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 10
- -1 fluorine ketones Chemical class 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 230000002490 cerebral effect Effects 0.000 claims description 6
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 5
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims description 5
- 229930003347 Atropine Natural products 0.000 claims description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 5
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 5
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 5
- 102000015554 Dopamine receptor Human genes 0.000 claims description 5
- 108050004812 Dopamine receptor Proteins 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 5
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 5
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 5
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 claims description 5
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 5
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical compound C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims description 5
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 5
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 5
- 229940100198 alkylating agent Drugs 0.000 claims description 5
- 239000002168 alkylating agent Substances 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 230000003444 anaesthetic effect Effects 0.000 claims description 5
- YUENFNPLGJCNRB-UHFFFAOYSA-N anthracen-1-amine Chemical compound C1=CC=C2C=C3C(N)=CC=CC3=CC2=C1 YUENFNPLGJCNRB-UHFFFAOYSA-N 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical class C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 5
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 5
- 229960000396 atropine Drugs 0.000 claims description 5
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims description 5
- 229960001081 benzatropine Drugs 0.000 claims description 5
- 229960002802 bromocriptine Drugs 0.000 claims description 5
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical class C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 5
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims description 5
- 229960004484 carbachol Drugs 0.000 claims description 5
- 190000008236 carboplatin Chemical compound 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- 239000000812 cholinergic antagonist Substances 0.000 claims description 5
- 229960000975 daunorubicin Drugs 0.000 claims description 5
- 229960003638 dopamine Drugs 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000003540 gamma secretase inhibitor Substances 0.000 claims description 5
- 229960003987 melatonin Drugs 0.000 claims description 5
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 5
- 239000002858 neurotransmitter agent Substances 0.000 claims description 5
- 229960004851 pergolide Drugs 0.000 claims description 5
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical class C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 5
- 229960005253 procyclidine Drugs 0.000 claims description 5
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 5
- 239000012217 radiopharmaceutical Substances 0.000 claims description 5
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 5
- 239000000018 receptor agonist Substances 0.000 claims description 5
- 229940044601 receptor agonist Drugs 0.000 claims description 5
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 5
- 229960002646 scopolamine Drugs 0.000 claims description 5
- 229960001032 trihexyphenidyl Drugs 0.000 claims description 5
- 235000013311 vegetables Nutrition 0.000 claims description 5
- 229960003048 vinblastine Drugs 0.000 claims description 5
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 5
- 230000002555 anti-neurodegenerative effect Effects 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 108010022394 Threonine synthase Proteins 0.000 claims description 3
- 102000005497 Thymidylate Synthase Human genes 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940046836 anti-estrogen Drugs 0.000 claims description 3
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 3
- 239000003972 antineoplastic antibiotic Substances 0.000 claims description 3
- 229960004046 apomorphine Drugs 0.000 claims description 3
- 239000000328 estrogen antagonist Substances 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 230000002607 hemopoietic effect Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 150000003057 platinum Chemical class 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 230000032258 transport Effects 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 abstract description 11
- 230000031998 transcytosis Effects 0.000 abstract description 8
- 230000004770 neurodegeneration Effects 0.000 abstract description 5
- 239000000969 carrier Substances 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 47
- 210000002889 endothelial cell Anatomy 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 37
- 208000032612 Glial tumor Diseases 0.000 description 27
- 206010018338 Glioma Diseases 0.000 description 27
- 210000003712 lysosome Anatomy 0.000 description 21
- 230000001868 lysosomic effect Effects 0.000 description 21
- 230000008685 targeting Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 11
- 210000001163 endosome Anatomy 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 238000011068 loading method Methods 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- 230000012202 endocytosis Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000000869 mutational effect Effects 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108010019160 Pancreatin Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101000835089 Mus musculus Transferrin receptor protein 1 Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 108010071673 magnetoferritin Proteins 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108010046015 ferritin receptor Proteins 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RBKASMJPSJDQKY-RBFSKHHSSA-N tirilazad Chemical group O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 RBKASMJPSJDQKY-RBFSKHHSSA-N 0.000 description 2
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 108010006205 fluorescein isothiocyanate bovine serum albumin Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005155 tirilazad Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
本发明公开了一种穿越血脑屏障的纳米药物载体,所述载体能够靶向脑部病灶(脑部肿瘤或者其他神经退行性疾病),所述穿越血脑屏障的靶向性药物载体包含全重链人铁蛋白或其功能片段重建体或突变体。其穿越血脑屏障的方式为受体介导的转胞吞作用。本发明所述的药物载体将为脑瘤或神经退行性疾病的治疗提供一种有效的纳米药物载体。
Description
PCT国内申请,说明书已公开。
Claims (14)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710109495.5A CN108503704A (zh) | 2017-02-27 | 2017-02-27 | 穿越血脑屏障的纳米药物载体 |
CN2017101094955 | 2017-02-27 | ||
PCT/CN2018/077295 WO2018153372A1 (zh) | 2017-02-27 | 2018-02-26 | 穿越血脑屏障的纳米药物载体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110337444A true CN110337444A (zh) | 2019-10-15 |
CN110337444B CN110337444B (zh) | 2024-02-20 |
Family
ID=63252406
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710109495.5A Pending CN108503704A (zh) | 2017-02-27 | 2017-02-27 | 穿越血脑屏障的纳米药物载体 |
CN201880010782.3A Active CN110337444B (zh) | 2017-02-27 | 2018-02-26 | 穿越血脑屏障的纳米药物载体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710109495.5A Pending CN108503704A (zh) | 2017-02-27 | 2017-02-27 | 穿越血脑屏障的纳米药物载体 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11707527B2 (zh) |
CN (2) | CN108503704A (zh) |
WO (1) | WO2018153372A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991561A (zh) * | 2020-08-26 | 2020-11-27 | 中国科学院上海高等研究院 | 一种高效穿过血脑屏障的寡聚核苷酸/原子精细纳米团簇复合物及其制备方法以及应用 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110179997B (zh) * | 2018-08-08 | 2020-02-14 | 昆山新蕴达生物科技有限公司 | 一种用于糖尿病治疗的纳米药物载体及其组合药物 |
WO2021008454A1 (zh) * | 2019-07-12 | 2021-01-21 | 昆山新蕴达生物科技有限公司 | 基于铁蛋白重链亚基的药物载体 |
CN111411120B (zh) * | 2020-04-01 | 2022-04-08 | 中国农业大学 | 一种锌离子诱导铁蛋白自组装包埋活性小分子的方法 |
CN112321719B (zh) * | 2020-07-28 | 2023-03-17 | 磐石锦程生物科技(北京)有限公司 | 一种药物载体蛋白及其应用 |
WO2022179536A1 (zh) * | 2021-02-25 | 2022-09-01 | 昆山新蕴达生物科技有限公司 | 铁蛋白重链亚基突变体及其应用 |
CN115137839A (zh) * | 2021-03-30 | 2022-10-04 | 南京纳么美科技有限公司 | 靶向-共装载亲/疏水药物的铁蛋白笼纳米载体及其应用 |
CN114832116B (zh) * | 2022-05-19 | 2024-01-26 | 沈阳药科大学 | 基于小胶质细胞表型调节和脑内铁清除的ros响应型纳米载体及其制备方法与应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090142360A1 (en) * | 2007-01-29 | 2009-06-04 | Chyna Llc | Use of ferritin to treat iron deficiency disorders |
WO2012152222A1 (zh) * | 2011-05-12 | 2012-11-15 | 中国科学院生物物理研究所 | 一种双功能肿瘤诊断试剂及方法 |
WO2012160333A2 (en) * | 2011-05-24 | 2012-11-29 | Chyna Llc | Recombinant yeast |
CN104013599A (zh) * | 2014-05-28 | 2014-09-03 | 中国科学院生物物理研究所 | 一种肿瘤特异性靶向给药的药物载体及其应用 |
CN104587480A (zh) * | 2015-02-02 | 2015-05-06 | 首都医科大学 | 一种穿越血脑屏障的纳米材料及其制备方法与应用 |
CN104650186A (zh) * | 2015-03-09 | 2015-05-27 | 中国药科大学 | 一种能够与TfR1特异性结合的活性肽及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018053434A1 (en) * | 2016-09-16 | 2018-03-22 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
-
2017
- 2017-02-27 CN CN201710109495.5A patent/CN108503704A/zh active Pending
-
2018
- 2018-02-26 WO PCT/CN2018/077295 patent/WO2018153372A1/zh active Application Filing
- 2018-02-26 US US16/489,302 patent/US11707527B2/en active Active
- 2018-02-26 CN CN201880010782.3A patent/CN110337444B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090142360A1 (en) * | 2007-01-29 | 2009-06-04 | Chyna Llc | Use of ferritin to treat iron deficiency disorders |
WO2012152222A1 (zh) * | 2011-05-12 | 2012-11-15 | 中国科学院生物物理研究所 | 一种双功能肿瘤诊断试剂及方法 |
WO2012160333A2 (en) * | 2011-05-24 | 2012-11-29 | Chyna Llc | Recombinant yeast |
CN104013599A (zh) * | 2014-05-28 | 2014-09-03 | 中国科学院生物物理研究所 | 一种肿瘤特异性靶向给药的药物载体及其应用 |
CN104587480A (zh) * | 2015-02-02 | 2015-05-06 | 首都医科大学 | 一种穿越血脑屏障的纳米材料及其制备方法与应用 |
CN104650186A (zh) * | 2015-03-09 | 2015-05-27 | 中国药科大学 | 一种能够与TfR1特异性结合的活性肽及其应用 |
Non-Patent Citations (5)
Title |
---|
LUCIANA MOSCA ET AL.: "Use of Ferritin-Based Metal-Encapsulated Nanocarriers as Anticancer Agents", 《APPL. SCI.》 * |
MASUDA, T. ET AL.: "GenBank:3AJQ_A", 《GENBANK》 * |
OTA, T. ET AL.: "GenBank:BAG54435.1", 《GENBANK》 * |
PAOLO SANTAMBROGIO ET AL.: "Production and Characterization of Recombinant Heteropolymers of Human Ferritin H and L Chains", 《THE JOURNAL OF BIOLOGICACLH EMISTRY》 * |
ZHANG, S. ET AL.: "GenBank:5GN8_A", 《GENBANK》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111991561A (zh) * | 2020-08-26 | 2020-11-27 | 中国科学院上海高等研究院 | 一种高效穿过血脑屏障的寡聚核苷酸/原子精细纳米团簇复合物及其制备方法以及应用 |
Also Published As
Publication number | Publication date |
---|---|
US11707527B2 (en) | 2023-07-25 |
WO2018153372A1 (zh) | 2018-08-30 |
CN110337444B (zh) | 2024-02-20 |
CN108503704A (zh) | 2018-09-07 |
US20200138960A1 (en) | 2020-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110337444A (zh) | 穿越血脑屏障的纳米药物载体 | |
Nakase et al. | Arginine-rich cell-penetrating peptide-modified extracellular vesicles for active macropinocytosis induction and efficient intracellular delivery | |
KR101263212B1 (ko) | 신규한 세포막 투과성 펩타이드 및 그의 용도 | |
CN102770764B (zh) | 对给定靶标具有亲和力的人脂质运载蛋白2(Lcn2,hNGAL)的突变蛋白 | |
CN109476713A (zh) | 工程改造的肉毒杆菌神经毒素 | |
US10316061B2 (en) | Synthesis of cell penetrating peptides for drug delivery and stem cell applications | |
Zhang et al. | Functionalized cell nucleus-penetrating peptide combined with doxorubicin for synergistic treatment of glioma | |
KR20030078935A (ko) | 혈관 형성 조절에 유용한 트립토파닐-tRNA 신세타제기원 폴리펩타이드 | |
CN102264755A (zh) | 靶向vegfr-1/nrp-1的肽 | |
WO2019209051A1 (ko) | 개질된 미토콘드리아 및 이의 용도 | |
CN109563151A (zh) | 用于治疗癌症的方法和组合物 | |
JPWO2005014625A1 (ja) | 脳移行活性を有するポリペプチド、およびその利用 | |
GB2555131A (en) | Nanocage | |
CN107531757A (zh) | 细胞毒性hexim1肽和其用途 | |
CN108456254A (zh) | 一种tcs-穿膜肽-肿瘤蛋白酶底物肽融合蛋白、其制备方法和用途 | |
Ru et al. | A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity | |
Todorova | Comparative analysis of the methods of drug and protein delivery for the treatment of cancer, genetic diseases and diagnostics | |
US20210189396A1 (en) | Plant viral rna delivery nanoparticles and uses thereof | |
JP7456676B2 (ja) | 新規な細胞透過性ペプチド及びその用途 | |
CN107236046A (zh) | 一种重组人内皮抑素融合蛋白及其制备方法和应用 | |
CN106749561B (zh) | 一种嗜麦芽窄食单胞菌外膜蛋白及其应用 | |
US20060189558A1 (en) | Delivery of substances to cells | |
CN103865899B (zh) | 具有vegfr2/kdr受体特异性的融合毒素及其编码基因与应用 | |
ES2648487T3 (es) | Antagonistas de factor de crecimiento endotelial vascular y métodos para su uso | |
EP3031820A1 (en) | JC Polyomavirus VLP (virus-like particle) with a targeting peptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |